Payers

Pharmacists have an important role to play in the success of value-based payment models, according to panelists who discussed their health plan’s value initiatives at the Academy of Managed Care Pharmacy Nexus 2020 meeting.

In a panel discussion at the Academy of Managed Care Pharmacy Nexus 2020 meeting, experts discussed driving factors of and barriers to the use of real-world evidence by payers in oncology decision-making.

As the coronavirus disease 2019 (COVID-19) pandemic threatens to worsen the opioid crisis, payers must rapidly deploy policies to ensure care for individuals with opioid use disorder.

The authors, from RxCrossroads by McKesson, discuss the impact of copay accumulator and maximizer programs.

A new national study is highlighting disparities in morbidity and barriers to care that face patients with chronic obstructive pulmonary disease (COPD) living in in rural areas.

Natera’s Signatera ctDNA test will determine study eligibility and treatment effectiveness in HR-positive, HER2-negative breast cancer patients.

More Humana doctors are taking on full global risk under Medicare Advantage than are still using traditional fee-for-service.

The relatively few examples of commercially funded condition-specific bundled payments provide insights into how to spread this alternative payment model further in the private insurance market.

More biosimilars are hitting the US market, but marketplace dynamics have made it difficult to take advantage of these therapies.

Pediatric patients who had a referral from their pediatric rheumatologist and continued insurance coverage saw decreased delays when transitioning to an adult rheumatology clinic.

Trump administration officials said the new payment incentives represent the biggest change in kidney care in decades.

The authors used health care claims and survey data to identify a strategy that might promote life satisfaction while advancing equity in an insured population.

A FAIR Health review finds a dramatic drop in dental claims in March and April 2020 due to COVID-19.

Reports of Medicare Advantage (MA) patients receiving higher-quality care for their cardiovascular disease prompted this comparison study of patients with heart failure enrolled in Medicare fee-for-service plans (FFS) and MA plans.

A decision-analytic model could save more than $7 million in overall ineffective health care costs per 1000 patients by predicting which patients with rheumatoid arthritis (RA) will have an inadequate response to anti–tumor necrosis factor therapies.

Members of Congress introduce a bill to force Medicare to cover a drug they say will protect CKD patients during the COVID-19 pandemic.

Telehealth claim lines increased 4132% nationally from June 2019 to June 2020, rising from 0.16% of medical claim lines in June 2019 to 6.85% in June 2020, according to new data from FAIR Health’s Monthly Telehealth Regional Tracker.

Data presented during the European Society for Cardiology 2020 Congress were a follow-up to the presentation of VERTIS CV at the American Diabetes Association Scientific Sessions in June.

Despite progress from disease-modifying antirheumatic drugs, there is still a far greater long-term risk of undergoing total knee and hip arthroplasties in patients with rheumatoid arthritis.

A Dutch study shows how genetic testing can help couples avoid passing devastating kidney diseases to their children, but it raises issues of disparities.

The challenges of complying with payer mandates in biosimilars were discussed in a webinar sponsored by The American Journal of Managed Care® and The Center for Biosimilars®.

When a crisis hits and members become isolated, how can a health plan continue to play an active role in maintaining their health?

Proposed CMS rules would make it easier for state Medicaid programs to smooth the way for value-based contracts for high-cost gene therapies.

Given the constraints prevalent post-COVID-19, Dr Mark Fendrick, director of the University of Michigan Center for Value-Based Insurance Design, stresses that it is now more important than ever for the health care industry to prioritize payment reform, value-based benefit design, and novel policy initiatives.

Despite concerns, legislation to cap out-of-pocket payments for specialty drugs has not been shown to shift costs to health plans, thereby increasing insurance premiums, according to a study published in New England Journal of Medicine.

Hinge Health announced the expansion of its clinical and technical musculoskeletal (MSK) capabilities to cover the full continuum of MSK care. The move will provide the most complete back and joint health solution to employers and health plans.

The coronavirus disease 2019 (COVID-19) vaccines that are leading the pack are utilizing a new vaccine technology that has never been approved for human use by the FDA. As a result, there are a lot of unknowns.

Patients with myeloproliferative neoplasms (MPNs) have high disease burden, and management of their disease can vary widely to include watchful waiting, phlebotomy, or drug therapy.

The race for a coronavirus disease 2019 (COVID-19) vaccine is one of the most urgent public health challenges, with multiple vaccine candidates entering phase 3 trials and case counts around the world steadily climbing. MJH Life Sciences™ will host a free webinar with the top minds in infectious disease, virology, and vaccinology to discuss the latest trial information on vaccines.